Trial Profile
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Fludarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 27 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
- 02 Jun 2009 New trial record